Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Best match
Most recent
14h
Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis Biotherapeutics
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...
BioPharma Dive
14h
Incyte sinks on setback for drugs acquired in $750M buyout
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
To lead Medicare, Medicaid
Education secretary pick
Iran's uranium stockpile
Commerce secretary pick
OK's landmine aid to UKR
Liam Payne’s funeral
MX gray wolf found dead
5 Brazilian officers arrested
Hush money case delayed
Clemency decision delayed
US housing starts tumble
Atmospheric river alert
Gold hits one-week high
To lead energy committee
Aid trucks looted in Gaza
Attorney for accusers sued
22 trapped for 2 hours
Subway chokehold trial
Jeffries wins reelection
UKR fires US-made missiles
Recommended content reset
Victims sue Colorado county
Hacker accessed Gaetz file?
Lakers to honor Pat Riley
Crash ratings get update
Updates nuclear doctrine
Super Heavy Starship launch
Bulls legend dies at 81
Jets fire GM Joe Douglas
Microsoft pitches AI 'agents'
Feedback